Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery.

Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, Tomei S, Fox BA, Gajewski TF, Marincola FM, Butterfield LH.

J Transl Med. 2011 Sep 19;9:155. doi: 10.1186/1479-5876-9-155.

2.

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.

Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, HÃ¥kansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML.

Clin Cancer Res. 2011 May 15;17(10):3064-76. doi: 10.1158/1078-0432.CCR-10-2234. Epub 2011 May 10. Review.

3.

Novel technologies and emerging biomarkers for personalized cancer immunotherapy.

Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H, Song W, Stack EC, Wang E, Whiteside TL, Zhao Y, Zwierzina H, Butterfield LH, Fox BA.

J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016. Review.

4.

Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016.

Gulley JL, Repasky EA, Wood LS, Butterfield LH.

J Immunother Cancer. 2017 Jul 18;5(1):55. doi: 10.1186/s40425-017-0262-1. Review.

5.

The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program.

Balwit JM, Hwu P, Urba WJ, Marincola FM.

J Transl Med. 2011 Jan 31;9:18. doi: 10.1186/1479-5876-9-18. Review.

6.

Systematic evaluation of immune regulation and modulation.

Stroncek DF, Butterfield LH, Cannarile MA, Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F, Lee PP, Marincola F, Rutella S, Siebert JC, Trinchieri G, Seliger B.

J Immunother Cancer. 2017 Mar 21;5:21. doi: 10.1186/s40425-017-0223-8. eCollection 2017. Review.

7.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH.

J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. Review.

8.

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.

Dobbin KK, Cesano A, Alvarez J, Hawtin R, Janetzki S, Kirsch I, Masucci GV, Robbins PB, Selvan SR, Streicher HZ, Zhang J, Butterfield LH, Thurin M.

J Immunother Cancer. 2016 Nov 15;4:77. doi: 10.1186/s40425-016-0179-0. eCollection 2016. Review.

9.

Applications of systems biology in cancer immunotherapy: from target discovery to biomarkers of clinical outcome.

Guhathakurta D, Sheikh NA, Meagher TC, Letarte S, Trager JB.

Expert Rev Clin Pharmacol. 2013 Jul;6(4):387-401. doi: 10.1586/17512433.2013.811814. Review.

PMID:
23927667
10.

[Biomarkers for cancer immunotherapy].

Kawakami Y, Kawase Y, Ohizumi A, Noji S, Sakurai T, Fujita T.

Nihon Rinsho. 2012 May;70(5):759-66. Review. Japanese.

PMID:
22619998
11.

Implementing liquid biopsies into clinical decision making for cancer immunotherapy.

Quandt D, Dieter Zucht H, Amann A, Wulf-Goldenberg A, Borrebaeck C, Cannarile M, Lambrechts D, Oberacher H, Garrett J, Nayak T, Kazinski M, Massie C, Schwarzenbach H, Maio M, Prins R, Wendik B, Hockett R, Enderle D, Noerholm M, Hendriks H, Zwierzina H, Seliger B.

Oncotarget. 2017 Jul 18;8(29):48507-48520. doi: 10.18632/oncotarget.17397. Review.

12.

Biomarkers for glioma immunotherapy: the next generation.

Sims JS, Ung TH, Neira JA, Canoll P, Bruce JN.

J Neurooncol. 2015 Jul;123(3):359-72. doi: 10.1007/s11060-015-1746-9. Epub 2015 Feb 28. Review.

13.

Improved endpoints for cancer immunotherapy trials.

Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J.

J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97. doi: 10.1093/jnci/djq310. Epub 2010 Sep 8. Review.

14.

New cancer biomarkers deriving from NCI early detection research.

Verma M, Srivastava S.

Recent Results Cancer Res. 2003;163:72-84; discussion 264-6. Review.

PMID:
12903844
15.

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.

Mittal D, Gubin MM, Schreiber RD, Smyth MJ.

Curr Opin Immunol. 2014 Apr;27:16-25. doi: 10.1016/j.coi.2014.01.004. Epub 2014 Feb 14. Review.

16.

Bioinformatics for cancer immunotherapy target discovery.

Olsen LR, Campos B, Barnkob MS, Winther O, Brusic V, Andersen MH.

Cancer Immunol Immunother. 2014 Dec;63(12):1235-49. doi: 10.1007/s00262-014-1627-7. Epub 2014 Oct 26. Review.

PMID:
25344903
17.

Biomarkers and correlative endpoints for immunotherapy trials.

Morse MA, Osada T, Hobeika A, Patel S, Lyerly HK.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e287. Review.

18.

Breast cancer and immunology: biomarker and therapeutic developments.

Santa-Maria CA, Park SJ, Jain S, Gradishar WJ.

Expert Rev Anticancer Ther. 2015;15(10):1215-22. doi: 10.1586/14737140.2015.1086270. Epub 2015 Sep 10. Review.

PMID:
26358181
19.

Advancing Immune and Cell-Based Therapies Through Imaging.

Ponomarev V.

Mol Imaging Biol. 2017 Jun;19(3):379-384. doi: 10.1007/s11307-017-1069-7. Review.

20.

Cancer vaccines: identification of biomarkers predictive of clinical efficacy.

Harrop R.

Hum Vaccin Immunother. 2013 Apr;9(4):800-4. doi: 10.4161/hv.23032. Epub 2013 Apr 1. Review.

Supplemental Content

Support Center